Fuji Pharma CoFRA:FUP +2.54%87 3-Year ROIIC % is 6.57 as of Sep. 2025, which is 59% above its 10-year median of 4.12. GuruFocus rates FRA:FUP with a GF Score™ of 87/100 and a GF Value™ of €9.98. The stock has 3 warning signs investors should review. Among 944 Drug Manufacturers companies, Fuji Pharma Co ranks better than 54.56% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Fuji Pharma Co's 3-Year ROIIC % for the quarter that ended in Sep. 2025 was 6.57%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Fuji Pharma Co's 3-Year ROIIC % or its related term are showing as below:
FRA:FUP's 3-Year ROIIC % is ranked better than 54.56% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.635
vs FRA:FUP: 6.57
Fuji Pharma Co (FRA:FUP) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Fuji Pharma Co 3-Year ROIIC % Related Terms
Fuji Pharma Co 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Fuji Pharma Co's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Fuji Pharma Co's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fuji Pharma Co 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Fuji Pharma Co's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Fuji Pharma Co's 3-Year ROIIC % falls into.
Fuji Pharma Co's 3-Year ROIIC % for the quarter that ended in Sep. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 21.582 (Sep. 2025) - 19.3067088 (Sep. 2022) )
/
( 464.58 (Sep. 2025) - 460.289 (Sep. 2022) )
=
2.2752912
/
4.291
=
53.02%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Fuji Pharma Co (FRA:FUP) has a 3-Year ROIIC % of 6.57 as of Sep. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Fuji Pharma Co and its competitors. This is 59% above median its historical median of 4.12. According to the industry distribution chart, Fuji Pharma Co ranks #429 out of 944 companies in the Drug Manufacturers industry, placing it in the top 45.4%.
Is Fuji Pharma Co's 3-Year ROIIC % too high?
Fuji Pharma Co's current 3-Year ROIIC % of 6.57 is 59% above median its 10-year median of 4.12. The Drug Manufacturers industry median 3-Year ROIIC % is 3.64. Fuji Pharma Co's value of 6.57 is 80.7% above this industry median. Based on the distribution chart, Fuji Pharma Co ranks #429 out of 944 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Fuji Pharma Co has a GF Score™ of 87/100, reflecting its overall financial health beyond just this single metric.
How does Fuji Pharma Co's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Fuji Pharma Co ranks #429 out of 944 companies for 3-Year ROIIC %. This puts Fuji Pharma Co in the upper half of its industry. The industry median 3-Year ROIIC % is 3.64. Fuji Pharma Co's value of 6.57 is 80.7% above this benchmark. While the company's 10-year median is 4.12 vs. the industry median of 3.64, Fuji Pharma Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.64, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fuji Pharma Co's current 3-Year ROIIC % of 6.57 is 80.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Fuji Pharma Co and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fuji Pharma Co's current 3-Year ROIIC % is 6.57, which is 59% above median its own 10-year median of 4.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fuji Pharma Co stock overvalued right now?
Fuji Pharma Co (FRA:FUP) has a current 3-Year ROIIC % of 6.57. The stock's GF Value™ is €9.98, compared to a current price of €10.10 — trading 1.2% above its estimated fair value. The current 3-Year ROIIC % is 6.57, which is 59% above median its 10-year median of 4.12 and 80.7% above the Drug Manufacturers industry median of 3.64. Fuji Pharma Co's overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Fuji Pharma Co (FRA:FUP), the current 3-Year ROIIC % is 6.57 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fuji Pharma Co (FRA:FUP) Overvalued in 2026?
Based on GuruFocus' analysis, Fuji Pharma Co stock appears to be overvalued.
The current stock price of €10.10 is trading 1.2% above its estimated GF Value™ of €9.98.
Key valuation signals for FRA:FUP:
3-Year ROIIC %: 6.57 (59% above median its 10-year median of 4.12)
GF Value™: €9.98 vs. price of €10.10 (1.2% above fair value)
Industry Position: 80.7% above the Drug Manufacturers median (#429 of 944)
No single metric tells the full story. See the FRA:FUP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fuji Pharma Co Ltd is involved in the development, manufacture, and marketing of pharmaceutical products, such as injection agents, internal drugs, drugs for external use, and diagnostic products. The group consists of a single segment, the pharmaceutical business.
87GF Score
Get the complete analysis for FRA:FUP
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:FUP has been successfully added to your 
